Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.335 USD | +3.26% | -10.32% | -34.14% |
01:24pm | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
05-10 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.14% | 2.68B | |
+28.31% | 48.16B | |
-0.24% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.98% | 25.59B | |
-22.69% | 18.96B | |
+8.59% | 12.92B | |
+29.89% | 12.03B | |
-1.73% | 11.77B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equalweight, Raises Price Target to $20 From $15